Monroe Capital (MRCC) - NASDAQ
  • Dec. 14, 2015, 11:20 AM
    • The price of oil has stabilized, but the major averages are moving lower, Treasury yields are moving higher in front of this week's expected Fed rate hike, and high-yield continues to sell off (with more funds gating withdrawals/selling holdings).
    • It all adds up to continued panicky liquidation in the business development complex. Prospect Capital (PSEC -4.8%), Fifth Street Finance (FSC -4.1%), Ares Capital (ARCC -4.9%), FS Investment (FSIC -3.4%), Triangle Capital (TCAP -4.8%), TICC Capital (TICC -9.1%), PennantPark Investment (PNNT -4.3%), New Mountain Finance (NMFC -5.8%), Monroe Capital (MRCC -4.5%), Oxford Lane (OXLC -10.4%).
    • ETFs: BDCL, BDCS, BIZD, FGB
    | Dec. 14, 2015, 11:20 AM | 65 Comments
  • Sep. 29, 2015, 3:24 PM
    • It's not just about energy anymore, according to a BAML report. "The malaise is spreading." High-yield, says the team, "[is] a slow-moving train wreck that just seems to be accelerating."
    • Equity-type proxies for the high-yield market, business development companies are under major selling pressure again today, with already large discounts to NAVs growing even wider.
    • Previously: Ares Capital greenlighted for $100M in buybacks (Sept. 28)
    • Prospect Capital (PSEC -3.6%), Ares Capital (ARCC -2.7%), Apollo Investment (AINV -4%), TCP Capital (TCPC -5.4%), Monroe Capital (MRCC -4.5%), Oxford Lane Capital (OXLC -5.4%), PennantPark Investment (PNNT -1.8%), American Capital (ACAS -2.5%), Medley Capital (MCC -4.1%), Harris & Harris (TINY -5.4%)
    • ETFs: BDCL, BDCS, BIZD, FGB
    | Sep. 29, 2015, 3:24 PM | 45 Comments
  • Apr. 15, 2015, 11:15 AM
    • Monroe Capital (MRCC -3.6%) priced a 2.45M share secondary at $14.85 each for gross proceeds of about $36.4M. The underwriters have an option to buy another 367K shares at that price.
    • Previously: Monroe Capital files for secondary offering (April 14)
    | Apr. 15, 2015, 11:15 AM
Company Description
Monroe Capital Corp., a business development company, invests in lower middle-market companies located in the US and Canada with EBITDA upto $25 million and revenues upto $250 million. The fund invests across a broad range of sectors including healthcare & pharmaceuticals, business services,... More
Sector: Financial
Country: United States